Liver
Tocotrienols support Liver Health by reducing Fat Accumulation, Inflammation, Oxidative Stress, Fibrosis, and even Cancer risk.
Annatto-derived Delta- & Gamma- Tocotrienols (200–300 mg/day, 12–24 weeks) improved liver enzymes and reduced hepatic fat in NAFLD (Non-Alcoholic Fatty Liver Disease) in human clinical trial patients.
Delta- and Gamma- Tocotrienols cause reductions in liver enzymes (ALT, AST), liver fat content, and Inflammation markers. They improve Insulin Sensitivity, which is key in metabolic liver disease.
Tocotrienols downregulate NF-κB and pro-inflammatory Cytokines (TNF-α, IL-6). This reduces Chronic Liver Inflammation that contributes to Fibrosis and Cirrhosis progression.
Tocotrienols are potent antioxidants and protect Hepatocytes (liver cells) from Lipid Peroxidation (rusting) and Mitochondrial damage.
Tocotrienols suppress Hepatic Stellate Cell activation, slowing Fibrosis. They show anti-tumor effects in liver cancer studies (Hepatocellular Carcinoma), reducing Angiogenesis (formation of new blood vessels that feed the cancer) and promoting Apoptosis (programmed cell death) of malignant cancer cells.
Tocotrienols naturally suppress HMG-CoA reductase (the same enzyme targeted by Statins). This lowers Cholesterol and Triglyceride levels, indirectly benefiting Liver function.
Tocotrienols reduce Fibrosis, improved Antioxidant status, and lower Inflammation in liver injury animal models.
Tocotrienols protected Hepatocytes (liver cells) from Oxidative Stress and Apoptosis.
References
Anticancer Activity of Delta-Tocotrienol in Human Hepatocarcinoma: Involvement of Autophagy Induction (2024) https://pmc.ncbi.nlm.nih.gov/articles/PMC11311296/?utm_source=chatgpt.com
Assessing the efficacy of Tocotrienol-rich fraction vitamin E in obese children with Non-Alcoholic Fatty Liver Disease: a single-blind, randomized clinical trial (2024)
https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-024-04993-8?utm_source=chatgpt.com
Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review (2023) https://pmc.ncbi.nlm.nih.gov/articles/PMC9965814/?utm_source=chatgpt.com
Revisiting the Therapeutic Potential of Tocotrienol (2022)
https://pmc.ncbi.nlm.nih.gov/articles/PMC9544065/?utm_source=chatgpt.com
Comparison of Delta-Tocotrienol and Alpha- Tocopherol effects on Hepatic Steatosis and inflammatory biomarkers in patients with Non-Alcoholic Fatty Liver Disease: A randomized double-blind active-controlled trial (2022) https://www.sciencedirect.com/science/article/pii/S0965229922000681?utm_source=chatgpt.com
Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents (2021)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8295474/?utm_source=chatgpt.com
Delta- Tocotrienol supplementation improves biochemical markers of Hepatocellular injury and Steatosis in patients with Non-Alcoholic Fatty Liver Disease: A randomized, placebo-controlled trial (2020) https://pubmed.ncbi.nlm.nih.gov/32951743/
Regulation of inflammatory response and Oxidative Stress by Tocotrienol in a rat model of Non-Alcoholic Fatty Liver Disease (2020)
https://www.sciencedirect.com/science/article/pii/S1756464620304333?utm_source=chatgpt.com
Effects of Delta- Tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease (2018)
https://pmc.ncbi.nlm.nih.gov/articles/PMC6284694/?utm_source=chatgpt.com